EpiPen

As Insys Therapeutics Inc (NASDAQ: INSY) shifts from opioid therapies to cannabinoids and spray technology, one analyst sees an opportunity to buy in. The Rating Janney analyst Yun Zhong assumed coverage with a Buy rating and cut his price target from $16 to $11. The Thesis Insys forecasted at...

After nearly two years, the U.S. Food & Drug Administration has finally approved the generic versions of the EpiPen produced by Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA). What Happened? On Thursday, the FDA approved Teva's generic versions of the EpiPen and EpiPen Jr....

Analysts at Argus no longer hold a bullish view on Mylan N.V. (NASDAQ: MYL) after the company cut its full-year guidance and cautioned that its earnings per share will decline in 2017. The firm's Jasper Hellweg downgraded Mylan's stock rating from Buy to Hold as the stock is fairly valued at its...

Adamis Pharmaceuticals Inc (NASDAQ: ADMP) may have a major catalyst on the way in the next several days. Adamis could be on the brink of a third ruling from the U.S. Food and Drug Administration related to its leading product candidate, a pre-filled epinephrine syringe that could serve as a low-...

Commenting on Mylan N.V. (NASDAQ: MYL), Barclays said there's understandably reason to be skeptical that the company will win approval for its generic version of Copaxone now after years of promises. That said, the firm thinks Mylan's chances are better than current market expectations. Analysts...

Mylan N.V. (NASDAQ: MYL), which has faced a plethora of lawsuits in the past over its EpiPen, is now being saddled with another lawsuit, although this time around the parties involved go beyond the company and the plaintiffs. EpiPen And Its Legal Tussle EpiPen, or an epinephrine auto injector is...

Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) wants to stop egregious drug pricing issues, and Mallinckrodt PLC (NYSE: MNK) is its next target. Imprimis announced it will pursue a lower priced alternative to Mallinckrodt's HP Acthar Gel, which grossed sales of $1.3 billion in the prior year....

“While new approvals hurt Mylan N.V. (NASDAQ: MYL) on price (during Q3), the company has defended share effectively; a point management highlighted but we believe has been underappreciated,” Barclays’ Douglas D. Tsao said in a note. The analyst maintains an Equal-Weight rating on...

Short sellers pounced on this leading pharmacy operator in the most recent period. During that time, the company announced the availability of a cheap, generic EpiPen. The share price rose modestly between the most recent settlement dates. The latest data shows that the number of shares sold...

Shares of Mylan NV (NASDAQ: MYL) fell sharply Wednesday, after news broke that the EpiPen was being dropped from Cigna Corporation's (NYSE: CI) coverage list. As of January 7, Mylan's Epipen was dropped from Cigna’s prescription drug list. The EpiPen maker has come under...

Mylan NV (NASDAQ: MYL) faced its fair share of controversy earlier this year for increasing the price of its potentially life-saving EpiPen product by more than 400 percent over the past few years. On Friday, Mylan announced the launch of the authorized generic for EpiPen at a wholesale acquisition...

Mylan NV (NASDAQ: MYL) delivered a Q3 miss. Although management reiterated its 2018 earnings target, the company was not able to reverse sentiment “which has become increasingly negative in the wake of the Epipen controversy,” Barclays’ Douglas D. Tsao said in a report. He...

Investor sentiment on Mylan NV (NASDAQ: MYL) shares remain upbeat ahead of the third-quarter results Wednesday after the market closes. The biotech stock and peers within the space gained after Hillary Clinton lostthe presidential election. Past Performance In the first two quarters of the current...

Mylan NV (NASDAQ: MYL) over the weekend announced a $465 million settlement agreement with the Department of Justice over its EpiPen classification. The stock was up more than 11 percent to $40.13 in Monday's pre-market session. Several Wall Street analysts were quick to weigh in on the...